Neglected Tropical Disease Diagnostics Market: By Type (Conventional Method And Molecular Method), By Application (Clinical Labs, Hospitals /Clinics And Home Healthcare), By Disease (Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis And Others), By End Users (Hospitals, Clinical Labs And Home Healthcare), By Service Type (Centralized Service And Point Of Care Service), By Geography (North America, Europe, Asia Pacific, Latin America And MEA) and Forecast to 2030.

The Neglected Tropical Disease Diagnostics Market was valued at USD 7,872.1 million in 2023 and grew at CAGR of 4.9% during the forecast years (2024-2030). Neglected Tropical Diseases (NTDs) diagnosis refers to the process of identifying and detecting a variety of diseases, most common in low-income and tropical nations. Numerous illnesses, including leishmaniasis, dengue fever, and malaria, frequently go undetected and untreated, placing a heavy health burden on the afflicted communities. Factors driving growth of the market like regions with a high prevalence of NTDs drive the demand for diagnostics. These diseases include malaria, dengue fever, leishmaniasis, and others commonly found in tropical and subtropical areas. Additionally, public health awareness and initiative, technological advancement, government initiatives and regulatory support also drives the market growth. Moreover, collaborative efforts between governments, non-profit organizations, academia, and private sectors foster innovation and distribution of NTD diagnostics, addressing logistical and financial barriers.

In the field of neglected tropical disease (NTD) diagnostics, there are several challenges. Manufacturers and suppliers find it unattractive due to low profits and limited returns on investment. This uncertainty affects the quality of many NTD diagnostic products. However, changes in global and western regulatory rules for in vitro diagnostics (IVDs) have made procedures more expensive, disrupting the availability of some NTD diagnostics. For instance, Sanofi's drug fexinidazole, approved by the FDA in July 2021, treats human African trypanosomiasis (sleeping sickness) caused by T.b. gambiense. Sanofi collaborates with the WHO and Drugs for Neglected Diseases initiative. They plan to seek WHO prequalification and manage distribution through a donation program. They will also apply to the EMA to expand its use to treat another form of the disease, T.b. rhodesiense, in sub-Saharan Africa.

Recent Developments In The Neglected Tropical Disease Diagnostics Market

• In 2020, Food Drug and Administration approved Bayer’s Lampit for paediatric nifurtimox, for Chagas disease in children
• In 2020: GSK(through ViiV Healthcare) gained FDA approval for its paediatric label extension and formulation of dolutegravir (Tivicay PD), used to treat HIV/AIDS. 
• In 2020: Johnson & Johnsongained approval for its two-shot Ebola vaccine regimen (Zabdeno® and Mvabea®) from the European Medicines Agency (EMA).